SNAP aims to improve treatment outcomes for patients with Staphylococcus aureus bloodstream infections. This website provides information for participants, members of the public, and healthcare professionals about SNAP and information about Staphylococcus aureus bloodstream infections.
This trial is a first of its kind in that it is recruiting adults, paediatrics, and youth.
The study includes sites from Australia, New Zealand, Singapore, Canada, Israel, South Africa, Europe, the UK, and has the potential to expand to other regions.
Staphylococcus aureus bacteraemia (SAB) is one of the most serious bacterial infections worldwide. Read More >
Treatment for SAB largely depends on the resistance profile of the Staphylococcus aureus bacteria causing the infection. Read More >
Randomized controlled trials (RCTs) are the gold-standard method for generating evidence to show benefits of new therapies or interventions. Read More >
Learn more about why we’re studying treatments for S. aureus bloodstream infections in the SNAP trial.
Learn more about why we’re studying treatments for S. aureus bloodstream infections in the SNAP trial.
Subscribe to receive email updates about SNAP and the study results.
Follow us on Twitter
